All News
Suspending Methotrexate for Influenza Vaccination
Vaccinating our rheumatoid arthritis patients against influenza every year is a safety priorty. However immunosuppressive therapies pose a challenge to vaccine administration as their use can hamper vaccine immunogenicity.
Read ArticleAnti-IL-5 Success in Eosinophilic Granulomatosis with Polyangiitis
The NEJM reports success when using mepolizumab (anti-IL-5 monoclonal antibody) in a 52 week study of patients with eosinophilic granulomatosis with polyangiitis (EGPA).
Read ArticleActemra - First FDA Approved Drug for Giant Cell Arteritis
The FDA has approved subcutaneous tocilizumab for use in Giant Cell Arteritis based on the phase III GiACTA study that demonstrated that TCZ with steroids was superior to steroid therapy alone.
Read ArticleRituximab May Benefit Rheumatoid Lung
A retrospective study shows that rituximab treatment of RA-related interstitial lung disease may improve or forestall ILD progression.
Read ArticleHigh Mortality with ANCA Associated Vasculitis
Mortality remains high in patients with the types of vasculitis that are associated with the presence of antineutrophil cytoplasmic antibodies (ANCA), a meta-analysis in Annals of the Rheumatic Diseases determined.
Read ArticleVenous Thromboembolism Risk Factors in ANCA-Associated Vasculitis
A retrospective analysis of four European vasculitis trials analyzes the risk venous thromboembolism (VTE) with ANCA-associated vasculitis and shows that CRP, cutaneous and GI involvement and baseline creatinine were most associated with VTE risk.
Read ArticleThe RheumNow Week in Review – 21 April 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.com:
Read ArticleParadoxical Toxicities with TNF Inhibitors
Something is curiously wrong when a drug induces the disease it is intended to treat. Yet this phenomenon has been described with all five FDA-approved TNF inhibitors.
Read ArticleThe RheumNow Week in Review – 14 April 2017
Dr. Jack Cush reviews the past week's news, articles and advances from RheumNow.com.
Read ArticleStroke Risk Highest in the First Year of Lupus
Arkema et al has published in Annals of Rheumatic Disease a study showing that ischaemic and haemorrhagic stroke (CVA) is elevated in systemic lupus erythematosus (SLE) compared with the general population, especially in the first year.
Read ArticleHydroxychloroquine Underperforms in a Cutaneous Lupus Trial
Hydroxychloroquine has become a mainstay in the treatement of patients with systemic lupus erythematosus (SLE) with proven efficacy in managing many domains of lupus, including skin, joint, and other autoimmune features.
Read ArticleSteroids, DMARDs and Biologics have Same Low Risk of Infection During Pregnancy
Low rates of serious infections were observed in pregnant women receiving immunosuppressive therapies. Higher rates may be seen with steroid use in pregnancy and SIE trend towards lowest with DMARD or TNFi use.
Read ArticleThe RheumNow Week in Review – 24 March 2017
Dr. Jack Cush reviews news and highlights from the past week on RheumNow.com.
Read ArticleSjogren's Syndrome Foundation's 2017 Sjogren's Treatment Guidelines
Dr. Steven Carsons and an expert committee of the Sjogren's Syndrome Foundation have published a clinical practice guidelines (CPGs) and recommendations for the managment of Sjögren's syndrome.
Read ArticleLupus Hepatitis and Lupoid Hepatitis Reviewed
SLE-related hepatitis (“lupus hepatitis”) and “lupoid hepatitis” are 2 different diseases. The term "lupoid hepatitis", now known as autoimmune hepatitis (AIH), was first coined in 1959. AIH was initially called “lupoid hepatitis” by MacKay. A review by Adiga and Nugent reviews, defines and distinguishes between lupus-related hepatitis and lupoid hepatitis.
Read ArticleCheckpoint Inhibitors Causing Rheumatic Disease
Calabrese and Velcheti have reviewed the current understanding that underlies a new drug-induced rheumatic disease - checkpoint inhibitor arthritis and autoimmune disease.
Read ArticleThe RheumNow Week in Review – 17 March 2017
Dr. Jack Cush reviews highlights in the news from the past week at RheumNow.com. News on hepatitis C in RA and risk of hepatotoxicity; TNF inhibitor persistence in PsA; unnecessary injections in pre-operative OA knee patients; and a delay in the FDA decision on abaloparatide.
Read ArticleThe RheumNow Week in Review – 10 March 2017
Dr. Jack Cush reviews news and highlights from the past week on RheumNow.com. Sign up at RheumNow.com to received daily or weekly news, blogs and tweets on all things rheumatology
Read ArticleTargeting CD11b as Treatment for Lupus
Researchers from Rush University Medical Center have reported in the March 6 issue of the Journal of Clinical Investigation that engagement of the integrin CD11b with a novel compound, may improved outcomes in patients iwth systemic lupus erythematosus (SLE).
Read ArticleMeta-analysis Reveals Numerous Pregnancy Complications Associated with Lupus
On the heels of the recently published EULAR recommendations for the management of pregnancy in patients with systemic lupus erythematosus (SLE) and the anti-phospholipid syndrome (APS) comes a new meta-analysis published in the Journal of Autoimmunity on pregnancy outomes in lupus.
Read Article